パーキンソン病の認知症に対する補助技術の学際的なアプローチ
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。補助技術 (AT) は,パーキンソン病認知症 (PDD) やパーキンソン病による軽度の認知障害 (PD-MCI) の患者の日常的機能と安全性を向上させることができます. このレビューは,PDD/PD-MCI患者の生活の質を改善するためにATを使用する臨床医のガイドです.
科学分野
- 神経科学
- 回復医療
- 補助技術
背景
- パーキンソン病の認知症 (PDD) とパーキンソン病による軽度の認知障害 (PD-MCI) は,パーキンソン病 (PD) の一般的な非運動症状である.
- PDD/PD-MCIの認知機能低下は,コミュニケーション,安全性,独立性,社会的関係,そして介護者の負担に大きな影響を及ぼします.
- 支援技術 (AT) はこれらの課題を緩和し,生活の質を向上させるための潜在的な解決策を提供します.
研究 の 目的
- PDDとPD-MCIの患者に利用可能なアシスティヴ・テクノロジー (AT) を検討する.
- 分野間のリハビリテーションの観点から,ATの幅,機能性,有効性,利用を分析する.
- PDD/PD-MCIの管理におけるATの適切な使用と適応のための臨床ガイドを提供すること.
主な方法
- PDDとPD-MCIに関する既存の文献の体系的なレビュー
- 理学療法,職業療法,言語病理学の学際的な洞察を考慮したAT研究の分析.
- PDD/PD-MCIの特定のニーズに焦点を当てたサンプルサイズを含む試験の限界の評価
主要な成果
- 様々なATは,PDD/PD-MCIの集団における日常の機能,安全性,生活の質の改善の可能性を示しています.
- いくつかの大規模な研究は,ATの実践的な実施に関する貴重な洞察を提供します.
- 現在の研究の限界は,サンプルサイズが小さいことと認知機能の欠陥の不足です.
結論
- ATはPDD/PD-MCIの患者とその介護者にとって非常に有益です.
- このレビューは,ATの選択と適応のための学際的なガイドとして機能します.
- PDD/PD-MCIにおける最適のATの適用,訓練,実装を理解するためにさらなる研究が必要である.
関連する概念動画
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....